Biotech Values

[Mpower]

Even if one subscribes to the belief that TEVA is close to obtaining mL approval (which IMHO is not likely), there is a strong argument to be made that the FDA will refrain from acting on the other outstanding applications (TEVA/Amphastar mL applications), until the Sanofi v. FDA case winds down. (i.e. Goes to trial and appeals are exhausted) That could take several months.